Effects of GnRH and Raloxifen on the size of uterine lyomioma
Phase 3
- Conditions
- terine lyomioma.Noninflammatory disorder of uterus, unspecified
- Registration Number
- IRCT2014032816490N2
- Lead Sponsor
- Vice chancellor for research, Kurdistan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 53
Inclusion Criteria
not being menopausal, and having a history of lyomiomas with a minimum size of 40 mm and a maximum of 60 mm in one of the diameters of tumor.
Exclusion criteria: having metabolic disease, neoplasia disease, infectious diseases, blood disorders; history of venous thrombosis, liver disease, active rheumatoid arthritis; BMI greater than 30 or less than 18 kg/m2; hormone therapy in the last 6 months; surgery in the last 6 months; hypoechoic or calcified lyomiomas; endometrial abnormalities in sonography, and lesions of the cervix.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method terine leiomyomas size. Timepoint: Before and 90 days after treatment. Method of measurement: Sonography.
- Secondary Outcome Measures
Name Time Method Endometrial thickness. Timepoint: Before and 90 days after treatment. Method of measurement: Sonography.